✦ LIBER ✦

Effective chemotherapy for esophageal cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II

✍ Scribed by Steven E. Vogl; Edward Greenwald; Barry H. Kaplan

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 438 KB
Volume: 48
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19811215)48:12<2555::aid-cncr2820481202>3.0.co;2-l

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy of advanced head and neck c

Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule

✍ Steven E. Vogl; Barry H. Kaplan 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 2 views

Mitomycin-C, methotrexate, bleomycin and

Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck

✍ Steven E. Vogl; Harvey Lerner; Barry H. Kaplan; Fernando Camacho; James Cinberg; 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 2 views

Renal toxicity with cumulative doses of

Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion

✍ Norman Jaffe; Robert Keifer Iii; Resa Robertson; Ayten Cangir; Alexander Wang 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB

Chemotherapy for advanced head and neck

Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen

✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 2 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad